In this issue:
Oral orforglipron vs. semaglutide in type 2 diabetes
Tubeless AID vs. MDIs in type 1 diabetes
Associations of GLP-1 agonists and healthy lifestyle with CV outcomes in type 2 diabetes
Cause-specific mortality trends with and without diabetes in high-income settings
Oral semaglutide in early-stage symptomatic Alzheimer disease
Finerenone in type 1 diabetes and CKD
GDM risk increased by daily high temperature exposure
Association of ambient temperature with hypoglycaemia in type 1 diabetes
Contributions of bone microarchitecture to skeletal fragility in longstanding type 1 diabetes
Safety of semaglutide after dialysis initiation
Please login below to download this issue (PDF)